Literature DB >> 35974263

Serum protease-activated receptor (PAR-1) levels as a potential biomarker for diagnosis of inflammation in type 2 diabetic patients.

Sanjay Goyal1, Ankita Sood2, Isha Gautam2, Soumyadip Pradhan2, Puskar Mondal2, Gaaminepreet Singh3, Ravinder Singh Jaura2, Thakur Gurjeet Singh2, Raminderpal Singh Sibia1.   

Abstract

BACKGROUND: Inflammation is a prominent clinical manifestation in type 2 diabetes mellitus (T2DM) patients, often associated with insulin resistance, metabolic dysregulation, and other complications. AIM OF THE STUDY: The present study has been designed to check the serum levels of PAR-1 and correlate with various clinical manifestations and inflammatory cytokines levels in type 2 diabetic subjects.
MATERIAL AND METHODS: The study population was divided into two groups, healthy volunteers (n = 15): normal glycated hemoglobin (HbA1c) (4.26 ± 0.55) and type 2 diabetic subjects (n = 30): HbA1c levels (7.80 ± 2.41). The serum levels of PAR-1 (ELISA method) were studied in both groups and correlated with demographic parameters age, weight, body mass index (BMI), and conventional inflammation biomarkers like C-reactive protein (CRP), interleukin 6 (IL-6), interleukin 8 (IL-8), and tumour necrosis factor-alpha (TNF-α).
RESULTS: The demographic variables including the body weight (77.38 ± 10.00 vs. controls 55.26 ± 6.99), BMI (29.39 ± 3.61 vs. controls 25.25 ± 4.01), glycemic index HbA1c (7.80 ± 2.41 vs. controls 4.26 ± 0.55) were found to be statistically increased in T2DM subjects than the healthy control group. The levels of various inflammatory biomarkers and PAR-1 were significantly elevated in T2DM groups in comparison to healthy volunteers. The univariate and multivariate regression analysis revealed that elevated PAR-1 levels positively correlated with increased body weight, BMI, HbA1c, and inflammatory cytokines.
CONCLUSION: Our findings indicate that the elevated serum PAR-1 levels serve as an independent predictor of inflammation in T2DM subjects and might have prognostic value for determining T2DM progression.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Biomarker; Cytokines; Inflammation; Protease-activated receptor 1; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2022        PMID: 35974263     DOI: 10.1007/s10787-022-01049-0

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   5.093


  29 in total

1.  Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells.

Authors:  Nithiananthan Asokananthan; Peter T Graham; Joshua Fink; Darryl A Knight; Anthony J Bakker; Andrew S McWilliam; Philip J Thompson; Geoffrey A Stewart
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

2.  Relation between BMI and diabetes mellitus and its complications among US older adults.

Authors:  Natallia Gray; Gabriel Picone; Frank Sloan; Arseniy Yashkin
Journal:  South Med J       Date:  2015-01       Impact factor: 0.954

3.  Thrombin and PAR-1-AP increase proinflammatory cytokine expression in C6 cells.

Authors:  Yongyi Fan; Weizhen Zhang; Michael Mulholland
Journal:  J Surg Res       Date:  2005-09-06       Impact factor: 2.192

4.  Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.

Authors:  Silvio Antoniak; Jessica C Cardenas; Laura J Buczek; Frank C Church; Nigel Mackman; Rafal Pawlinski
Journal:  Cardiology       Date:  2016-11-24       Impact factor: 1.869

5.  Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.

Authors:  Jonas Ghouse; Jonas L Isaksen; Morten W Skov; Bent Lind; Jesper H Svendsen; Jørgen K Kanters; Morten S Olesen; Anders G Holst; Jonas B Nielsen
Journal:  Diabetes Obes Metab       Date:  2019-11-18       Impact factor: 6.577

Review 6.  Inflammation and type 2 diabetes.

Authors:  M C Calle; M L Fernandez
Journal:  Diabetes Metab       Date:  2012-01-16       Impact factor: 6.041

7.  Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1.

Authors:  Amanda Hurley; Mindy Smith; Tatiana Karpova; Rebecca B Hasley; Natalya Belkina; Stephen Shaw; Nariman Balenga; Kirk M Druey; Erin Nickel; Beverly Packard; Hiromi Imamichi; Zonghui Hu; Dean Follmann; James McNally; Jeanette Higgins; Michael Sneller; H Clifford Lane; Marta Catalfamo
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

8.  Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study.

Authors:  Jolien de Jager; Jacqueline M Dekker; Adriaan Kooy; Piet J Kostense; Giel Nijpels; Rob J Heine; Lex M Bouter; Coen D A Stehouwer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-02       Impact factor: 8.311

9.  Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis.

Authors:  M A Cunningham; E Rondeau; X Chen; S R Coughlin; S R Holdsworth; P G Tipping
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

10.  The role of protease-activated receptor 1 signaling in CD8 T cell effector functions.

Authors:  Hui Chen; Mindy Smith; Jasmin Herz; Tong Li; Rebecca Hasley; Cecile Le Saout; Ziang Zhu; Jie Cheng; Andres Gronda; José A Martina; Pablo M Irusta; Tatiana Karpova; Dorian B McGavern; Marta Catalfamo
Journal:  iScience       Date:  2021-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.